The Effects of Adjuvant Tamoxifen Use on Macula Pigment Epithelium Optical Density, Visual Acuity and Retinal Thickness in Patients with Breast Cancer

References

• Cheung KL. Endocrine therapy for breast cancer: an overview. Breast. 2007;16(4):327–43. doi:10.1016/j.breast.2007.03.004.
   PubMed Web of Science ®Google Scholar
• Cammarata PR, Chu S, Moor A, Wang Z, Yang S-H, Simpkins JW. Subcellular distribution of native estrogen receptor α and β subtypes in cultured human lens epithelial cells. Exp Eye Res. 2004;78:861–71.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kinoshita Y, Tachibana M, Matsushima Y, Kobayashi Y, Adachi W, Sotozono C, Kinoshita S. Expression of sex steroid hormone receptors in human cornea. Curr Eye Res. 2001;22(1):28–33. doi:10.1076/ceyr.22.1.28.6980.
   PubMed Web of Science ®Google Scholar
• Spelsberg H, Klueppel M, Reinhard T, Glaeser M, Niederacher D, Beckmann MW, Sundmacher R. Detection of Oestrogen receptors (ER) α and β in conjunctiva, lacrimal gland, and tarsal plates. Eye. 2004;18(7):729. doi:10.1038/sj.eye.6701314.
   PubMed Web of Science ®Google Scholar
• Sullivan DA. Tearful relationships? Sex, hormones, the lacrimal gland, and aqueous-deficient dry eye. Ocul Surf. 2004;2(2):92–123. doi:10.1016/S1542-0124(12)70147-7.
   PubMedGoogle Scholar
• Auw-Haedrich C, Feltgen N. Estrogen receptor expression in meibomian glands and its correlation with age and dry-eye parameters. Graefes Arch Clin Exp Ophthalmol. 2003;241(9):705–09. doi:10.1007/s00417-003-0699-4.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Harvey JT, Hewlett B. Immunohistochemical evidence for estrogen receptors in meibomian glands. Ophthalmology. 2000;107(1):180–84. doi:10.1016/S0161-6420(99)00040-8.
   PubMed Web of Science ®Google Scholar
• Munaut C, Lambert V, Noël A, Frankenne F, Deprez M, Foidart J-M, Rakic J-M. Presence of oestrogen receptor type β in human retina. Br J Ophthalmol. 2001;85(7):877–82. doi:10.1136/bjo.85.7.877.
   PubMed Web of Science ®Google Scholar
• Marin-Castano ME, Elliot SJ, Potier M, Karl M, Striker LJ, Striker GE, Csaky KG, Cousins SW. Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44(1):50–59. doi:10.1167/iovs.01-1276.
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Machalinska A, Vereb Z, Salminen A, Petrovski G, Kauppinen A. Estrogen signalling in the pathogenesis of age-related macular degeneration. Curr Eye Res. 2015;40(2):226–33. doi:10.3109/02713683.2014.925933.
   PubMed Web of Science ®Google Scholar
• Gupta PD, Johar SK, Nagpal K, Vasavada AR. Sex hormone receptors in the human eye. Surv Ophthalmol. 2005;50(3):274–84. doi:10.1016/j.survophthal.2005.02.005.
   PubMed Web of Science ®Google Scholar
• Ogueta SB, Schwartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human eye: influence of gender and age on gene expression. Invest Ophthalmol Vis Sci. 1999;40:1906–11.
   PubMed Web of Science ®Google Scholar
• Garcia‐Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol. 2008;20:705–12.
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Liu F, Marquis K, Muniz L, Pangalos MN, Ring RH, Whiteside GT, Brandon NJ. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol. 2009;2(3):215–36. doi:10.2174/1874467210902030215.
   PubMedGoogle Scholar
• Morissette M, Le Saux M, D’Astous M, Jourdain S, Al Sweidi S, Morin N, Estrada-Camarena E, Mendez P, Garcia-Segura LM, Di Paolo T. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J Steroid Biochem Mol Biol. 2008;108(3–5):327–38. doi:10.1016/j.jsbmb.2007.09.011.
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431–42. doi:10.1056/NEJMra023246.
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. J Clin Oncol. 2005;23(3):619–29. doi:10.1200/JCO.2005.09.121.
   PubMed Web of Science ®Google Scholar
• Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008;63(3):163–81. doi:10.1097/OGX.0b013e31816400d7.
   PubMed Web of Science ®Google Scholar
• Jordan VC, Brodie AMH. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72(1):7– 25. doi:10.1016/j.steroids.2006.10.009.
   PubMed Web of Science ®Google Scholar
• Musa MA, Khan OF, Cooperwood JS. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem. 2007;14(11):1249–61. doi:10.2174/092986707780598023.
   PubMed Web of Science ®Google Scholar
• Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;276(40):36869–72. doi:10.1074/jbc.R100029200.
   PubMed Web of Science ®Google Scholar
• Higgins MJ, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010;12(1):7–15. doi:10.1007/s11912-009-0076-5.
   PubMed Web of Science ®Google Scholar
• Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem. 2009;55(10):1770–82. doi:10.1373/clinchem.2008.121756.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. doi:10.1016/S0140-6736(05)66544-0.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84. doi:10.1016/S0140-6736(11)60993-8.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. doi:10.1016/S0140-6736(12)61963-1.
   PubMed Web of Science ®Google Scholar
• Junghans A, Sies H, Stahl W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch Biochem Biophys. 2001;391(2):160–64. doi:10.1006/abbi.2001.2411.
   PubMed Web of Science ®Google Scholar
• van de Kraats J, Kanis MJ, Genders SW, van Norren D. Lutein and zeaxanthin measured separately in the living human retina with fundus reflectometry. Invest Ophthalmol Vis Sci. 2008;49(12):5568–73. doi:10.1167/iovs.08-1939.
   PubMed Web of Science ®Google Scholar
• Barker FM, Snodderly DM, Johnson EJ, Schalch W, Koepcke W, Gerss J, Neuringer M. Nutritional manipulation of primate retinas, V: effects of lutein, zeaxanthin, and n–3 fatty acids on retinal sensitivity to blue-light–induced damage. Invest Ophthalmol Vis Sci. 2011;52(7):3934–42. doi:10.1167/iovs.10-5898.
   PubMed Web of Science ®Google Scholar
• Arteni -A-A, Fradot M, Galzerano D, Mendes-Pinto MM, Sahel J-A, Picaud S, Robert B, Pascal AA. Structure and conformation of the carotenoids in human retinal macular pigment. PLoS One. 2015;10(8):e0135779. doi:10.1371/journal.pone.0135779.
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ozawa Y, Kurihara T, Kubota S, Yuki K, Noda K, Kobayashi S, Ishida S, Tsubota K. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53(5):971–79. doi:10.1007/s00125-009-1655-6.
   PubMed Web of Science ®Google Scholar
• Li S-Y, Fu Z-J, Ma H, Jang W-C, So K-F, Wong D, Lo ACY. Effect of lutein on retinal neurons and oxidative stress in a model of acute retinal ischemia/reperfusion. Invest Ophthalmol Vis Sci. 2009;50(2):836–43. doi:10.1167/iovs.08-2310.
   PubMed Web of Science ®Google Scholar
• Zengin MO, Cinar E, Kucukerdonmez C. The effect of nicotine on choroidal thickness. Br J Ophthalmol. 2014;98(2):233–37. doi:10.1136/bjophthalmol-2013-304044.
   PubMed Web of Science ®Google Scholar
• Creuzot-Garcher C, Koehrer P, Picot C, Aho S, Bron AM. Comparison of two methods to measure macular pigment optical density in healthy subjects. Invest Ophthalmol Vis Sci. 2014;55(5):2941–46. doi:10.1167/iovs.13-13568.
   PubMed Web of Science ®Google Scholar
• Klein BEK, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. Am J Ophthalmol. 2000;130(3):322–26. doi:10.1016/S0002-9394(00)00474-8.
   PubMed Web of Science ®Google Scholar
• Vingerling JR, Dielemans I, Witteman JCM, Hofman A, Grobbee DE, De Jong PTVM. Macular degeneration and early menopause: a case-control study. BMJ. 1995;310(6994):1570–71. doi:10.1136/bmj.310.6994.1570.
   PubMed Web of Science ®Google Scholar
• Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age‐related macular degeneration: results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 1997;25(4):13–15. doi:10.1111/ceo.1997.25.issue-4.
   Google Scholar
• Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy: third National Health and Nutrition Examination Survey. Ophthalmology. 1995;102(3):371–81. doi:10.1016/S0161-6420(95)31012-3.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BEK, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the beaver dam eye study. Ophthalmology. 1997;104(1):7–21. doi:10.1016/S0161-6420(97)30368-6.
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research G. Risk factors associated with age-related macular degeneration: a case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology. 2000;107(12):2224–32. doi:10.1016/s0161-6420(00)00409-7.
   PubMed Web of Science ®Google Scholar
• Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A Review J Clin Oncol. 1996;14(3):1018–26. doi:10.1200/JCO.1996.14.3.1018.
   PubMed Web of Science ®Google Scholar
• Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JES, Margolese RG, Mathen MK, Bowman DM. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125(4):493–501. doi:10.1016/S0002-9394(99)80190-1.
   PubMed Web of Science ®Google Scholar
• Chung H, Kim D, Ahn SH, gone KJ, Lee JY, Lim JY, Yoon YH. Early detection of tamoxifen-induced maculopathy in patients with low cumulative doses of tamoxifen. Ophthalmic Surg Lasers Imaging. 2010.
   Google Scholar
• Cronin BG, Lekich CK, Bourke RD. Tamoxifen therapy conveys increased risk of developing a macular hole. Int Ophthalmol. 2005;26(3):101–05. doi:10.1007/s10792-005-5424-3.
   PubMedGoogle Scholar
• Eisner A, Toomey MD, Falardeau J, Samples JR, Vetto JT. Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. Breast Cancer Res Treat. 2007;106(2):161–70. doi:10.1007/s10549-006-9486-3.
   PubMed Web of Science ®Google Scholar
• Lim IL, Loo AVP, Subrayan V, Khang TF, See MH, Alip A, Taib NAM. Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. Breast. 2018 Jun;39:117–22. Epub 2018 Apr 13. doi:10.1016/j.breast.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Einar Stefansson, editor. Acta Ophthalmologica, Special Issue: Abstracts from the 2014 European Association for Vision and Eye Research Conference.  EVER 2014 – European Association for Vision & Eye Research Annual Meeting; 2014 Oct 1-4; Nice, France. Copenhagen (Denmark): John Wiley & Sons; 2014.
   Google Scholar
• Azar G, Quaranta-El Maftouhi M, Masella JJ, Mauget-Faÿsse M. Macular pigment density variation after supplementation of lutein and zeaxanthin using the Visucam® 200 pigment module: impact of age-related macular degeneration and lens status. J Fr Ophtalmol. 2017;40(4):303–13. doi:10.1016/j.jfo.2016.11.009.
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, Sperduto R, Ferris FL, Group AR. The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012;119(11):2282–89. doi:10.1016/j.ophtha.2012.05.027.
   PubMed Web of Science ®Google Scholar